Powered by

Horizon Pharma swoops in on Raptor

Sep 12, 2016 - The Deal Pipeline

Horizon Pharmaceuticals plc (HZNP)   continued its M&A maneuvering on Monday with an $800 million agreement to buy Raptor Pharmaceutical Corp. (RPTP)  to expand its rare disease business and extend its international presence.

The Dublin company said it would offer $9 a share for Novato, Calif.-based Raptor. That's almost 21% above Raptor's most recent price of $7.45 before trading in the shares was suspended.

Horizon bought Crealta Holdings LLC for $510 million in...